Sareum Holdings PLC Sierra Oncology has reported its 2018 Results (4733R)
01 March 2019 - 1:04AM
UK Regulatory
TIDMSAR
RNS Number : 4733R
Sareum Holdings PLC
28 February 2019
(AIM: SAR) 28 February 2019
Sareum Holdings plc
("Sareum" or "the Company")
Licence holder for SRA737, Sierra Oncology, has reported its
2018 Year End Results
Sareum Holdings plc (AIM: SAR), the specialist small molecule
drug development business, notes that Sierra Oncology ("Sierra"),
the licence holder advancing clinical cancer candidate SRA737, has
announced its 2018 full year results in which it provides a review
of progress made on the development of SRA737.
In the statement, Sierra CEO Nick Glover commented "We have
enrolled a substantial number of patients into the two ongoing
trials for our oral Chk1 inhibitor, SRA737, and remain on track to
report clinical data from these studies in the first half of
2019."
The full announcement can be found by clicking here:
Sareum also notes that it will publish its interim results for
the six months to end December 2018 on 4 March 2019.
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser)
Chris Fielding / James Sinclair-Ford 020 7220 1666
Hybridan LLP (Nominated Broker)
Claire Noyce 020 3764 2341
Citigate Dewe Rogerson (Media enquiries)
Shabnam Bashir/ Mark Swallow/ David
Dible 020 7638 9571
Notes for editors:
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics, to improve the treatment of
cancer and autoimmune disease. The Company generates value through
licensing its candidates to international pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum's leading clinical-stage programme, SRA737, a novel
Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed
Sierra Oncology, is in Phase 2 clinical trials targeting ovarian
and other advanced cancers. The key role of Chk1 in cancer cell
replication and DNA damage repair suggests that SRA737 may have
broad application as a targeted therapy in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
Sareum is also advancing internal programmes focused on distinct
dual tyrosine kinase 2 (TYK2) /Janus kinase 1 (JAK1) inhibitors
through preclinical development as therapies for autoimmune
diseases (SDC-1801) and cancers (SDC-1802). TYK2 and JAK1 have
roles in pro-inflammatory responses in autoimmune diseases (e.g.
psoriasis, rheumatoid arthritis, inflammatory bowel diseases and
lupus) and tumour cell proliferation in certain cancers (e.g.
T-cell acute lymphoblastic leukaemia and some solid tumours). The
Company is targeting first human clinical trials in each indication
in 2020.
The Company also has an Aurora+FLT3 inhibitor targeting
haematological cancers, which is at the preclinical development
stage.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit www.sareum.co.uk
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORLLFEVFDITFIA
(END) Dow Jones Newswires
February 28, 2019 09:04 ET (14:04 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024